An Experimental H.I.V. Vaccine Fails in Africa
The New York Times
Researchers ended a large trial in South Africa after finding that an experimental vaccine offered little protection.
An advanced H.I.V. vaccine trial in Africa has been shut down after data showed the shots offered only limited protection against the virus, researchers announced on Tuesday. The vaccine, made by Johnson & Johnson, is one in a long line found to offer little defense against H.I.V., one of medicine’s most intractable adversaries. One candidate vaccine even increased the risk of infection. Another trial was halted last year in South Africa after a different experimental vaccine failed to offer sufficient protection. Some 1.5 million people were infected with H.I.V. worldwide in 2020, and 38 million are living with the infection.More Related News